| Yoon Yeup / Ph.D. |
Name : Yoon Yeup Ph.D.
Department : 삼성융합의과학원
Title : Professor
Office : SMC Campus
E-mail : yoonyeup@skku.edu
Homepage :
Lab. title : Molecular Oncology Lab.
Related Department : Department of Health Sciences and Technology,Department of Medical Device Management and Research
Print
PDF Download
|
|
■ Careers 1983 B.S., Seoul National University 1985 M.S., Seoul National University 1994 Ph.D., State Univ. New York at Buffalo (Roswell Park Cancer Institute) 1994-1995 Post-doc, Roswell Park Cancer Institute 1995-1997 JungAm Biotechnology Research Institute 1997-2008 Senior Scientist ~ Vice Director, Mogam Biotechnology Research Institute 2008-2013 President, Mogam Biotechnology Research Institute 2013-Present Professor, Research Institute for Future Medicine Director, Office of R&BD, Samsung Medical Center ■ Research Summary Although the various anticancer therapeutics have been developed, the response rate for the patients with different types of cancer to the available drugs shows the significant variations due to the biological heterogeneity of cancer. Especially, many of the recently developed targeted therapies showed the beneficiary efficacies on the very minor portion of the patients. The development of the cancer biomarkers to identify the group of patients likely to respond to a specific treatment in prospective manner will be the critical issues on the clinical application of the personalized therapies as well as the drug developments. Our lab will focus on the discovery and developments of the tools such as antibodies for the various targets in regards to the personalized treatments and companion diagnosis of the cancer. The generation of the highly specific and sensitive antibodies will facilitate the development of the diagnostic tools as well as the drug candidate. The main research area will be 1) discovery and developments of novel antibodies for the companion diagnosis and therapeutics, 2) molecular functional validation, 3) clinical validation, and 4) the elucidation of the molecular and cellular mechanisms. ■ Keyword: Companion diagnosis, personalized therapy, antibody discovery & development ■ Selected Publications 1) Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Lee JK, et al. Nat Genet. 2018 Oct;50(10):1399-1411. 2) Pharmacokinetics, Biodistribution, and Toxicity Evaluation of Anti-SEMA3A (F11) in In Vivo Models. Lee J, Kim D, Son E, Yoo SJ, Sa JK, Shin YJ, Yoon Y, Nam DH. Anticancer Res. 2018 May;38(5):2803-2810. 3) nti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth. Lee J, et al. Cancer Res Treat. 2018 Jul;50(3):1009-1022. |
